{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T22:06:03Z","timestamp":1705183563323},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":4984,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1995,9]]},"abstract":"<jats:p><jats:bold>Abstract: <\/jats:bold> Twenty\u2010nine late chronic and accelerated phase chronic myelogenous leukaemia (CML) patients were entered in a pilot study designed to test the therapeutic efficacy of treatment with interferon\u2010\u03b1 (IFN\u2010\u03b1) and low\u2010dose cytosine arabinoside (ARA\u2010C). IFN\u2010\u03b1 was administered at a dose of 2\u201310 \u00d7 10<jats:sup>6<\/jats:sup> IU\/day and ARA\u2010C at 15 mg\/m<jats:sup>2<\/jats:sup>\/day for 14 days each month. The treatment was well tolerated by 73% of the patients. Side effects were mainly asthenia, anorexia, anaemia and piastrinopenia. Haematological and cytogenetic responses were evaluated in the 19 patients who received more than 6 cycles. Four complete haematological response, 7 partial haematological response, 6 minor haematological response, 2 stable disease were obtained in this patient group. Two complete cytogenetic responses and 2 minor cytogenetic responses were detected in these patients. Suppression of secondary Ph' positive clones which appeared during the previous IFN\u2010\u03b1 treatment was documented in 3 accelerated phase patients after ARA\u2010C was added to their IFN\u2010\u03b1 treatment. It would therefore seem that late chronic and accelerated phase CML patients benefit from combined IFN\u2010\u03b1\/ARA\u2010C treatment and achieve haematological and cytogenetic responses not obtained during previous treatment without being exposed to undue toxicity. However, we cannot judge whether it offers any advantage in terms of survival.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1995.tb00248.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T05:11:31Z","timestamp":1279429891000},"page":"184-188","source":"Crossref","is-referenced-by-count":7,"title":["Interferon\u2010\u03b1 plus low\u2010dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients"],"prefix":"10.1111","volume":"55","author":[{"given":"A.","family":"Ferrajoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"Liberati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Caricchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Donti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Morra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lazzarino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. R.","family":"Betti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood.V72.2.642.642","article-title":"Interferon alpha\u20102b as therapy for Philadelphia positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration","volume":"72","author":"Alimena G.","year":"1988","journal-title":"Blood"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199209053562"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-7-532"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199403243301204"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198604243141701"},{"key":"e_1_2_1_7_2","first-page":"233a","article-title":"Low dose cytosine arabinoside in early and advanced chronic granulocytic leukemia","volume":"66","author":"Sokal J.","year":"1986","journal-title":"Blood"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870101)59:1<197::AID-CNCR2820590137>3.0.CO;2-8"},{"key":"e_1_2_1_9_2","first-page":"287","article-title":"Cytogenetics and molecular analysis in chronic myelogenous leukemia patients treated by interferon and chemotherapy","volume":"32","author":"Guilhot F.","year":"1990","journal-title":"Nouv Rev Fr Hematol"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1200\/JCO.1992.10.5.772","article-title":"Treatment of advanced stages of Philadelphia chromosome\u2010positive chronic myelogenous leukemia with interferon\u2010\u03b1 and low dose cytarabine","volume":"10","author":"Kantajian HM","year":"1992","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(93)90079-Z"},{"key":"e_1_2_1_12_2","first-page":"479","volume-title":"The chromosomes in human cancer and leukemia","author":"Sandberg AA.","year":"1990"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(90)90015-3"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1994.tb01306.x"},{"key":"e_1_2_1_15_2","unstructured":"GuilhotF. TanzerJ.Randomized trial of interferon with or without cytosine arabinoside in treatment of chronic myeloid leukemia. Proceedings International Society Hematology Meeting1991:311a."},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000204580"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1995.tb00248.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1995.tb00248.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T20:59:00Z","timestamp":1698353940000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1995.tb00248.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,9]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1995,9]]}},"alternative-id":["10.1111\/j.1600-0609.1995.tb00248.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1995.tb00248.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,9]]}}}